MDS-GLOBAL-LTD
25.6.2019 10:02:03 CEST | Business Wire | Press release
MDS Global Ltd, a leading BSS-as-a-Service provider today announced that iD Mobile, one of the UK's largest mobile virtual network operators, has engaged in a new contract with the company, adopting MDS Global's CMP 8, a fully cloud-enabled Monetisation Platform designed to scale on-demand for new subscriber and business growth.
Seeking greater flexibility to integrate social media and other self-serve and community applications, and to take advantage of the benefits of using Google's Cloud infrastructure, iD Mobile's move to MDS Global's CMP 8, the BSS-as-a-service platform that underpins the company's VNOnDemand solution, offers on-demand scalability for growth. Fully enabled for any public or private environment, iD Mobile can deploy new features and services within hours, keeping with the demands of today's feature-hungry consumers.
The UK-based MVNO, offers customers an online and app-based portal giving them the freedom to tailor their iD Mobile package based on consumption requirements and habit. This facility increased the requirement for a reliable, solid, billing, reconciliation and assurance engine which provided efficient integration to this digital layer. This BSS foundation is MDS Global's CMP8 which offers the facility to plan for future advancements through digital touchpoints.
Gary Bunney, CEO, MDS Global said, "We are thrilled to have been involved with one of the UK's leading MVNOs and the company's ground-breaking achievements to date. iD Mobile's adoption of cloud-enabled CMP 8 and our new our contract reinforces the quality and versatility of our technology and its ability to support an MVNO at the start of its journey, right through to maturity and as it continues its growth."
iD Mobile will continue to take advantage of an integrated digital platform that flexibly manages monetisation, assurance and data-driven engagement, minimising new expenditure and skills. Functionally it provides them with the ability to:
- Manage customer experience in real-time.
- Access online order management and provisioning
- Provide superior customer care and billing
MDS Global will be exhibiting throughout the year in various countries as part of the MVNO Series of events. To find out more, please go to: https://www.mdsglobal.com/events/ .
About MDS Global
MDS Global, a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions look after all aspects of monetisation, assurance and customer steering for complex products and services. We offer a digital operating model in a DevOps context, which enhances stakeholder experiences and provides unprecedented business agility.
Headquartered in the UK, MDS Global’s customers include BT Enterprise (UK), eir (Ireland), iD Mobile from Dixons Carphone (UK), TalkTalk (UK), Telefónica (UK), Vodafone (Germany, Greece and NL), Orange (Belgium), KPN (Netherlands) and Telia (Denmark).
For further information: www.mdsglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190625005005/en/
Contact:
Martine Naughton MDS Global Email: martine.naughton@mdsglobal.com Tel: +44 (0) 7909 475815
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom